PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, announced today a partnership with the EuroSafe imaging campaign launched at ECR 2014, the annual meeting of the European Society for Radiology.
The aim of the EuroSafe imaging campaign is to raise awareness about radiation protection and to showcase Europe’s leading role in medical radiation protection. EOS imaging will participate in the campaign’s kickoff at ECR 2014. The EuroSafe exhibit will be a central feature of the meeting featuring posters from experts around the world on safety practices in pediatric CT and from many stakeholders in the wider field of radiation safety, including national radiological societies, subspecialty societies and other international societies.
EOS continues its stewardship in offering imaging services with the lowest possible exposure to radiation meeting the ALARA principle with the announcement that the Micro Dose feature has been granted a CE Mark for the 3D reconstruction of the spine and lower limb. The new feature, unveiled in October 2013 at the Journées Francaises de Radiologie (JFR) annual meeting, affords up to seven times less radiation than the company’s current low dose offering and lowers the dose associated with a pediatric frontal and lateral spine exam to the level of a week natural radiation on Earth. Dr. Brice Ilharreborde, a pediatric orthopaedist at Paris’ Robert Debré Hospital was one of the first physicians to use Micro Dose in 3D assessment and monitoring of scoliotic patients.
Dr. Ilharreborde said, "The EOS imaging system is the gold standard in care in pediatric orthopedic imaging, treatment planning and monitoring. The Micro Dose feature, today available for 3D treatment planning, gives surgeons and clinicians an even better tool to chart the safest, best possible course of treatment for their patients."
Marie Meynadier, CEO of EOS imaging, said, “We are encouraged that European radiology community has chosen to focus on the issue of responsible radiation exposure in diagnosis, treatment planning and monitoring. Since its inception, EOS has been a pioneer in the reduction of radiation exposure and leads the way to safer radiographic imaging thanks to our proprietary detection technology. We are pleased to share our continued work in reducing radiation exposure to as low as reasonably achievable levels with the Micro Dose offering, as well as its compatibility with 3D reconstruction and associated clinical tools. The outcomes of our initiatives will benefit all orthopaedic patients, from pediatric to adult.”
In addition to its partnership with EuroSafe, EOS imaging will exhibit at ECR 2014, March 6-10 at the Austria Center Vienna, Booth #625.
For further information about the Company or EOS®, the first full-body, low dose 2D/3D imaging system, please visit www.eos-imaging.com.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 102 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com
EOS imaging is listed on Compartment C of Euronext Paris
ISIN:
FR0011191766 – Ticker: EOSI
Next press release: 2013 annual results on April 8, 2014 (after market).
